Treatment of SYNGAP1 encephalopathy

Transdermal CBD administration effectively treats SYNGAP1 encephalopathy symptoms by reducing seizures and behavioral problems, offering a safer alternative to oral CBD with fewer adverse effects.

JP7870723B2Active Publication Date: 2026-06-05HARMONY BIOSCIENCES MANAGEMENT INC
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
HARMONY BIOSCIENCES MANAGEMENT INC
Filing Date
2020-09-16
Publication Date
2026-06-05

Smart Images

  • Figure 0007870723000011
    Figure 0007870723000011
  • Figure 0007870723000001
    Figure 0007870723000001
  • Figure 0007870723000002
    Figure 0007870723000002
Patent Text Reader

Abstract

The present technology relates to a method of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to a subject, wherein SYNGAP1 symptoms are treated in the subject.
Need to check novelty before this filing date? Find Prior Art